ClinicalTrials.gg
Active, not recruitingNCT03452579Updated Feb 28, 2025Results posted

Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM

A Phase 2 interventional study of Nivolumab and Standard Dose Bevacizumab in Glioblastoma, sponsored by David Peereboom. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by David Peereboom · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 97 studies testing bevacizumab in Glioblastoma — 8 open to participants now, 13 under way, 1 of them phase 3. Bevacizumab · Glioblastoma.

Enrollment
20th of 97
90 · median 48
Started
2018
with 3 others
Phase 2
57 of 97
3 open now
Primary completion
2020-12
later than 0 of 12 live
Registered
77th of 97
by date

Among the 97 studies testing bevacizumab in Glioblastoma, this one is the 20th largest by enrollment, is one of 4 that started in 2018, is one of 57 in phase 2, reaches primary completion later than 0 of the 12 other live ones, and was the 77th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

8 of the 97 studies testing bevacizumab in Glioblastoma are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 341 Glioblastoma studies recruiting now, 236 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies testing bevacizumab in Glioblastoma, or all of them as a file.
02

Study summary

The purpose of this study is to test the effectiveness (how well the drug works), safety and tolerability of an investigational drug called nivolumab (also known as BMS-936558) in glioblastoma (a malignant tumor, or GBM), when added to bevacizumab.

Nivolumab is an antibody (a kind of human protein) that is being tested to see if it will allow the body's immune system to work against glioblastoma tumors. Opdivo (nivolumab ) is currently FDA approved in the United States for melanoma (a type of skin cancer), non-small cell lung cancer, renal cell cancer (a type of kidney cancer), Hodgkin's lymphoma but is not approved in glioblastoma. nivolumab may help your immune system detect and attack cancer cells.

Bevacizumab is a drug which works on the blood vessel that supply the tumor and potentially can starve the tumor by cutting off the blood supply to these tumors. Bevacizumab is commercially available and FDA approved for individuals with recurrent glioblastoma.

This study has two study groups. Arm 1 will receive the study drug nivolumab 240mg and bevacizumab 10 mg (standard dose) every 2 weeks and Arm 2 will receive the study drug nivolumab 240 mg and bevacizumab 3 mg (low dose) every 2 weeks. A process will be used to assign participants, by chance, to one of the study groups. Neither participants nor doctors can choose which group participants are in. This is done by chance because no one knows if one study group is better or worse than the other. 90 total participants are expected to participate in this study (45 participants in each arm).

Your total participation in this study from the time you have signed the informed consent to your last visit, including follow-up visits, may be more than three years (depending on what effect the treatment has on your cancer, and how well you tolerate the treatment).

Read the detailed description

Primary Endpoint(s)

-To evaluate the efficacy of nivolumab when administered with standard and low bevacizumab dosing among recurrent glioblastoma patients as measured by the rate of overall survival at twelve months.

Secondary Endpoint(s)

  • To evaluate the safety and tolerability of nivolumab in combination with bevacizumab administered according to standard and low dosage schedules for recurrent glioblastoma patients.
  • To compare progression free survival (PFS) at 6 months of nivolumab when administered with standard and low bevacizumab dosing for recurrent glioblastoma patients.
  • To compare the overall survival rate of nivolumab when administered with standard and low bevacizumab dosing for recurrent glioblastoma patients.
  • To compare progression free survival (PFS) of when administered with standard and low bevacizumab dosing for recurrent glioblastoma patients.
  • To compare the objective response rate (ORR) of nivolumab and bevacizumab administered according to standard and low dosage schedules for recurrent glioblastoma patients

Study design and duration: This is a randomized, open-label, phase 2 safety study of nivolumab and bevacizumab administered according to standard and low dosage schedules in adult (≥ 18 years) participants with a first recurrence or second recurrence of glioblastoma (GBM). Participants must have received previous treatment with radiotherapy and one recurrence. The study will allow participants that require decadron up to 4mg/day to participate. Participants will undergo 1:1 randomization to receive treatment with either nivolumab (240 mg flat dosing IV every 2 weeks) and bevacizumab administered according to standard (10 mg/kg IV every 2 weeks; Arm A) and low (3 mg/kg IV every 2 weeks; Arm B) dosage schedules for recurrent glioblastoma participants. The study will allow participants that require decadron up to 4 mg/ day to participate in the study.

Note - In view of the Covid 19 crisis, all in person visits can be substituted for virtual visit. All nursing toxicity checks can be performed over the phone rather than in person

03

Conditions studied

  • Glioblastoma

Browse trials for

Keywords

  • Nivolumab
  • Bevacizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written and HIPAA authorization obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations
  • Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study, including disease assessment by MRI.
  • confirmed diagnosis of supratentorial glioblastoma
  • Previous treatment with at least radiotherapy
  • Documented first recurrence of GBM by diagnostic or contrast enhanced magnetic resonance imaging (MRI) performed within 21 days of randomization per RANO criteria.
  • If first recurrence of GBM is documented by MRI, an interval of at least 12 weeks after the end of prior radiation therapy is required unless there is either:

    • histopathologic confirmation of recurrent tumor, or
    • new enhancement on MRI outside of the radiotherapy treatment field
  • An interval of > 28 days and full recovery (i.e., no ongoing safety issues) from surgical resection prior to randomization.
  • performance status (KPS) of 70 or higher (Appendix 1)
  • > 12 weeks
  • Up to ten unstained slides of 5 microns thickness or a block of tissue will be required to be sent if tissue is available. If the tissue is not available then Principal investigator permissions is required prior to enrollment
  • Women of (WOCBP,) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 1 day prior to the start of study drug
  • Women must not be breastfeeding
  • WOCBP must use appropriate method(s) of from the time of enrollment for the duration of treatment with study drug (s) plus 5 half-lives of study drug (s) plus 6 months post treatment completion for a treatment arm A (nivolumab + standard dose bevacizumab)and treatment arm B (nivolumab + low dose bevacizumab).
  • Men who are sexually active with WOCBP must use contraceptive method such as male condom with spermicide. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for the duration of treatment with study drug (s) plus 5 half-lives of study drug (s) plus 90 days (duration of sperm turnover) for a total of 31 weeks post-treatment completion.
  • Women who are not of childbearing potential (i.e., who are or surgically sterile as well as azoospermic men) do not require contraception.
  • Azoospermic males and WOCBP who are continuously not heterosexually active are exempt from contraceptive requirements.
  • Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy. Investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the use of highly effective methods of contraception. Highly effective methods of contraception have a failure rate of \< 1% per year when used consistently and correctly.
  • At a minimum, subjects must agree to the use of two methods of contraception, with one method being highly effective and the other method being either highly effective or less effective as listed below:
  • HIGHLY EFFECTIVE METHODS OF CONTRACEPTION

    • Hormonal methods of contraception including combined oral contraceptive pills, vaginal ring, injectables, implants, and intrauterine devices (IUDs) such as Mirena® by WOCBP subjects or male subject's WOCBP partner.
    • Nonhormonal IUDs, such as ParaGard
    • Tubal ligation
    • Vasectomy.
    • Complete Abstinence* ---*Complete abstinence is defined as complete avoidance of heterosexual intercourse and is an acceptable form of contraception for all study drugs. Subjects who choose complete abstinence are not required to use a second method of contraception, but female subjects must continue to have pregnancy tests. Acceptable alternate methods of highly effective contraception must be discussed in the event that the subject chooses to forego complete abstinence.
  • LESS EFFECTIVE METHODS OF CONTRACEPTION

    • Diaphragm with spermicide
    • Cervical cap with spermicide
    • Vaginal sponge
    • Male Condom without spermicide*
    • Progestin only pills by WOCBP subjects or male subject's WOCBP partner
    • Female Condom* ---*A male and female condom must not be used together
  • Women of Child Bearing Potential (WOCBP)

    --A women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes. In addition, women under the age of 55 years must have a serum follicle stimulating hormone, (FSH) level > 40mIU/mL to confirm menopause.*

    ---*Women treated with hormone replacement therapy, (HRT) are likely to have artificially suppressed FSH levels and may require a in order to obtain a physiologic FSH level. The duration of the washout period is a function of the type of HRT used. The duration of the washout period below are suggested guidelines and the investigators should use their judgment in checking serum FSH levels. If the serum FSH level is > 40 mIU/ml at any time during the washout period, the woman can be considered postmenopausal:

    • 1 week minimum for vaginal hormonal products (rings, creams, gels)
    • 4 week minimum for transdermal products
    • 8 week minimum for oral products
  • Other parenteral products may require washout periods as long as 6 months Each of the criteria in the checklist that follows must be met in order for a patient to be considered eligible for this study. Use the checklist to confirm a patient's eligibility. The checklist must be completed for each patient and must be signed and dated by the treating physician.
  • Recovery from the toxic effects of prior therapy, with a minimum time of:

    • (≥) 28 days elapsed from the administration of any agent
    • (≥) 28 days elapsed from the administration of any prior cytotoxic agents, except
    • (≥)14 days from vincristine, ≥ 21 days from procarbazine, and ≥ 42 days from
    • nitrosureas
    • (≥) 14 days elapsed from administration of any non-cytotoxic agent (e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid)
  • Screening/Baseline laboratory values must meet the following criteria (using v5.0):

    • WBC ≥ 2000/uL
    • Neutrophils ≥ 1500/uL
    • ≥ 100x103/uL
    • ≥ 9.0 g/dL
    • Serum creatinine \< 1.5 x or (CrCl) > 40 mL/min (using the Cockcroft-Gault formula)

      • Female CrCl = (140 - age in years) x weight in kg x 0.85 /72 x serum creatinine in mg/dL
      • Male CrCl = (140 - age in years) x weight in kg x 1.00/72 x serum creatinine in mg/dL
    • ≤ 3x ULN
    • ALT≤ 3x ULN
    • Pregnancy test (serum)
    • ≤ 1.5x ULN (except subjects with Gilbert Syndrome, who can have
    • Total bilirubin \< 3.0 mg/dL)

Exclusion criteria

Exclusion Criteria:

  • More than two recurrences of GBM
  • Presence of extracranial , significant or tumors primarily localized to the brainstem or spinal cord.
  • Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.
  • Subjects with active, known or suspected disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring chronic and systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. Subjects have any other condition requiring systemic treatment with or other immunosuppressive agents within 14 days. Inhaled or topical steroids and adrenal replacement doses >10mg daily prednisone equivalent are permitted in absence of active autoimmune disease
  • Previous radiation therapy with anything other than standard radiation therapy (i.e., focally directed radiation) administered as therapy.
  • Previous treatment with carmustine wafer except when administered as first line treatment and at least 6 months prior to randomization
  • Previous bevacizumab or other VEGF or anti-angiogenic treatment
  • Previous treatment with a , PD-L1 or CTLA-4 targeted therapy
  • Evidence of > Grade 1 CNS hemorrhage on the baseline MRI scan
  • Inadequately controlled hypertension (defined as systolic blood pressure ≥160 mmHg and /or diastolic blood pressure ≥100 mmHg) within 7 days of first study treatment
  • Prior history of hypertensive crisis, hypertensive encephalopathy, reversible posterior leukoencephalopathy syndrome (RPLS);
  • Prior history of gastrointestinal diverticulitis, perforation, or abscess;
  • (i.e., active) cardiovascular disease, for example cerebrovascular accidents ≤ 6 months prior to study enrollment, myocardial infarction ≤ 6 months prior to study enrollment, unstable angina, (NYHA) Grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment;
  • Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to start of study treatment. Any previous venous thromboembolism ≥ Grade 3 within 3 months prior to start of study treatment;
  • History of pulmonary hemorrhage/hemoptysis ≥ grade 2 (defined as ≥ 2.5 mL bright red blood per episode) within 1 month prior to randomization;
  • History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation);
  • Current or recent (within 10 days of study enrollment) use of anticoagulants that, in the opinion of the investigator, would place the subject at significant risk for bleeding. Prophylactic use of anticoagulants is allowed;
  • Surgical procedure (including open , surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to first study treatment, or anticipation of need for major surgical procedure during the course of the study;
  • Minor surgical procedure (e.g., stereotactic biopsy within 7 days of first study treatment; placement of a vascular access device within 2 days of first study treatment);
  • History of intracranial abscess within 6 months prior to randomization;
  • History of active gastrointestinal bleeding within 6 months prior to randomization;
  • Serious, non-healing wound, active ulcer, or untreated bone fracture;
  • Subjects unable (due to existent medical condition, e.g., pacemaker or ICD device) or unwilling to have a head contrast enhanced MRI
  • Positive test for virus surface antigen (HBV sAg) or detectable virus ribonucleic acid (HCV RNA) indicating acute or chronic infection
  • Known history of testing positive for (HIV) or known acquired immunodeficiency syndrome (AIDS)
  • History of severe reaction to any monoclonal antibody
  • Patients that require decadron > 4 mg/ day or equivalent of steroids
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Active comparator
    Nivolumab + Standard Dose Bevacizumab

    nivolumab 240 mg IV and standard dose bevacizumab 10 mg/kg every 2 weeks until disease progression or unacceptable toxicity. Nivolumab is to be administered first. The second infusion will be bevacizumab, and will start no sooner than 10 minutes after completion of the nivolumab infusion

    Drug: Nivolumab · Drug: Standard Dose Bevacizumab

  • Experimental
    Nivolumab + Low Dose Bevacizumab

    nivolumab 240 mg IV and low dose bevacizumab 3mg/kg every 2 weeks until disease progression or unacceptable toxicity Nivolumab is to be administered first. The second infusion will be bevacizumab, and will start no sooner than 10 minutes after completion of the nivolumab infusion

    Drug: Nivolumab · Drug: Low Dose Bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival at 12 Months (OS-12)

    OS-12 is the percentage of participants in the analysis population who remain alive for at least twelve months following initiation of study therapy. Participants without efficacy evaluation data or without survival data will be censored at Day 1

    Time frame: Up to 12 months after beginning therapy

Secondary outcomes

  1. Progression-Free Survival (PFS) at Six Months

    The percentage of participants in the analysis population who remain progression-free for at least six months following initiation of study therapy. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions Participants without efficacy evaluation data or without survival data will be censored at Day 1

    Time frame: Up to six months after beginning treatment

  2. Overall Survival (OS)

    OS, as defined as number of participants alive from beginning of treatment up to 6 six months Participants without efficacy evaluation data or without survival data will be censored at Day 1

    Time frame: Up to six months after beginning treatment

  3. Overall Survival (OS)

    OS, as defined as the percentage of participants alive from beginning of treatment up to 18 months. Participants without efficacy evaluation data or without survival data will be censored at Day 1

    Time frame: Up to 18 months after beginning treatment

  4. Overall Response Rate (ORR)

    Proportion of participants in the analysis population who have complete response (CR) or partial response (PR) using Radiologic Assessment in Neuro-Oncology criteria (RANO) criteria. Participants without efficacy evalaluation data or survival data censored at day 1. Participants without measurable disease will not be included.

    Time frame: Up to 3 years after beginning treatment

  5. Progression-Free Survival

    Median time from allocation to first documented disease progression per RANO or death due to any cause, whichever occurs first. Those without efficacy eval. data or survival data censored at day 1 RANO - progressive disease: * (\>) 25% increase in sum of products of perpendicular diameters of measurable lesions (over best response \[smallest tumor size\] or baseline if no decrease) on stable/increasing corticosteroid doses * Any new measurable lesion that when added to change in initial tumor(s) exceeds 25% increase in x-sectional area. * Clear clinical deterioration not attributable to causes apart from tumor. Def. is left to discretion of PI but recommended is: Decline in KPS from 100 or 90 to \<= 70, decline in KPS of at least 20 from \<= 80, or decline in KPS from any baseline to \<= 50, for \>= 7 days, be considered neurologic deterioration, unless attributable to co-morbid events or changes in corticosteroid dose. * Failure to return for eval. due to death or deteriorating condition

    Time frame: Up to 3 years after beginning treatment

  6. Duration of Response

    Time from first RANO response to disease progression in participants who achieve a PR or better Participants without efficacy evaluation data or without survival data will be censored at Day 1

    Time frame: Up to 3 years after beginning treatment

07

Results

Posted Jan 13, 2025

Participant flow

Participant flow — Overall Study
MilestoneNivolumab + Standard Dose BevacizumabNivolumab + Low Dose Bevacizumab
Started4545
Completed32
Not completed4243
Withdrew: Death01
Withdrew: Withdrawal by subject20
Withdrew: Disease progression, relapse during active treatment3837
Withdrew: Physician decision11
Withdrew: Adverse event14

Outcome measures

PrimaryOverall Survival at 12 Months (OS-12)

OS-12 is the percentage of participants in the analysis population who remain alive for at least twelve months following initiation of study therapy. Participants without efficacy evaluation data or without survival data will be censored at Day 1

Time frame:
Up to 12 months after beginning therapy
Reported as:
Number · Percentage of participants
Overall Survival at 12 Months (OS-12)
Percentage of participantsNivolumab + Standard Dose BevacizumabNivolumab + Low Dose Bevacizumab
Overall Survival at 12 Months (OS-12)41.1 (26.1 to 56.1)37.7 (23.1 to 52.4)
SecondaryProgression-Free Survival (PFS) at Six Months

The percentage of participants in the analysis population who remain progression-free for at least six months following initiation of study therapy. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions Participants without efficacy evaluation data or without survival data will be censored at Day 1

Time frame:
Up to six months after beginning treatment
Reported as:
Number · Percentage of participants
Progression-Free Survival (PFS) at Six Months
Percentage of participantsNivolumab + Standard Dose BevacizumabNivolumab + Low Dose Bevacizumab
Progression-Free Survival (PFS) at Six Months46.7 (32.1 to 61.2)44.6 (29.4 to 59.8)
SecondaryOverall Survival (OS)

OS, as defined as number of participants alive from beginning of treatment up to 6 six months Participants without efficacy evaluation data or without survival data will be censored at Day 1

Time frame:
Up to six months after beginning treatment
Reported as:
Number · Percentage of participants
Overall Survival (OS)
Percentage of participantsNivolumab + Standard Dose BevacizumabNivolumab + Low Dose Bevacizumab
Overall Survival (OS)75.1 (62.3 to 87.9)57.4 (42.9 to 71.9)
SecondaryOverall Survival (OS)

OS, as defined as the percentage of participants alive from beginning of treatment up to 18 months. Participants without efficacy evaluation data or without survival data will be censored at Day 1

Time frame:
Up to 18 months after beginning treatment
Reported as:
Number · Percentage of participants
Overall Survival (OS)
Percentage of participantsNivolumab + Standard Dose BevacizumabNivolumab + Low Dose Bevacizumab
Overall Survival (OS)30.9 (15.7 to 46.1)22.5 (8.5 to 36.5)
SecondaryOverall Response Rate (ORR)

Proportion of participants in the analysis population who have complete response (CR) or partial response (PR) using Radiologic Assessment in Neuro-Oncology criteria (RANO) criteria. Participants without efficacy evalaluation data or survival data censored at day 1. Participants without measurable disease will not be included.

Time frame:
Up to 3 years after beginning treatment
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsNivolumab + Standard Dose BevacizumabNivolumab + Low Dose Bevacizumab
Overall Response Rate (ORR)1816
SecondaryProgression-Free Survival

Median time from allocation to first documented disease progression per RANO or death due to any cause, whichever occurs first. Those without efficacy eval. data or survival data censored at day 1 RANO - progressive disease: * (\>) 25% increase in sum of products of perpendicular diameters of measurable lesions (over best response \[smallest tumor size\] or baseline if no decrease) on stable/increasing corticosteroid doses * Any new measurable lesion that when added to change in initial tumor(s) exceeds 25% increase in x-sectional area. * Clear clinical deterioration not attributable to causes apart from tumor. Def. is left to discretion of PI but recommended is: Decline in KPS from 100 or 90 to \<= 70, decline in KPS of at least 20 from \<= 80, or decline in KPS from any baseline to \<= 50, for \>= 7 days, be considered neurologic deterioration, unless attributable to co-morbid events or changes in corticosteroid dose. * Failure to return for eval. due to death or deteriorating condition

Time frame:
Up to 3 years after beginning treatment
Reported as:
Median · months
Progression-Free Survival
monthsNivolumab + Standard Dose BevacizumabNivolumab + Low Dose Bevacizumab
Progression-Free Survival4.1 (3.2 to 7.0)5.6 (3.7 to 6.8)
SecondaryDuration of Response

Time from first RANO response to disease progression in participants who achieve a PR or better Participants without efficacy evaluation data or without survival data will be censored at Day 1

Time frame:
Up to 3 years after beginning treatment
Reported as:
Mean · months
Duration of Response
monthsNivolumab + Standard Dose BevacizumabNivolumab + Low Dose Bevacizumab
Duration of Response5.2 (3.5 to 6.6)5.2 (3.4 to 6.8)

Adverse events

Collected over Adverse events were collected while participants were on study up to 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab + Standard Dose Bevacizumab37/45 (82.2%)25/45 (55.6%)45/45 (100%)
Nivolumab + Low Dose Bevacizumab40/45 (88.9%)21/45 (46.7%)44/45 (97.8%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventNivolumab + Standard Dose BevacizumabNivolumab + Low Dose Bevacizumab
Generalized Muscle WeaknessMusculoskeletal and connective tissue disorders7/454/45
FatigueGeneral disorders6/451/45
Other NeurologicNervous system disorders2/455/45
HypertensionCardiac disorders4/453/45
CognitiveNervous system disorders4/451/45
Deep vein thrombosisCardiac disorders3/452/45
Pulmonary EmbolismCardiac disorders3/452/45
InfectionGeneral disorders3/451/45
Gait ImbalanceMusculoskeletal and connective tissue disorders3/453/45
HeadachesNervous system disorders3/450/45
Most frequent other events
Showing 10 of 35
Most frequent other events
EventNivolumab + Standard Dose BevacizumabNivolumab + Low Dose Bevacizumab
FatigueGeneral disorders29/4519/45
HeadacheNervous system disorders20/4512/45
Abnormal ElectrocytesInvestigations18/4515/45
DiarrheaGastrointestinal disorders17/4512/45
ProteinuriaRenal and urinary disorders15/4517/45
HypertensionCardiac disorders15/457/45
Lipase IncreasedInvestigations14/456/45
SeizureNervous system disorders14/4513/45
General Muscle WeaknessInvestigations12/4514/45
BleedBlood and lymphatic system disorders13/458/45

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Nivolumab + Standard Dose BevacizumabNivolumab + Low Dose BevacizumabTotal
Median60.7 (27.4 to 81.0)60.5 (27.7 to 86.4)60.6 (27.4 to 86.4)
Sex: Female, Male
Sex: Female, Male(Participants)Nivolumab + Standard Dose BevacizumabNivolumab + Low Dose BevacizumabTotal
Female131629
Male322961
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nivolumab + Standard Dose BevacizumabNivolumab + Low Dose BevacizumabTotal
Hispanic or Latino000
Not Hispanic or Latino434386
Unknown or Not Reported224
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nivolumab + Standard Dose BevacizumabNivolumab + Low Dose BevacizumabTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American303
White404282
More than one race000
Unknown or Not Reported123
Region of Enrollment
Region of Enrollment(participants)Nivolumab + Standard Dose BevacizumabNivolumab + Low Dose BevacizumabTotal
United States454590
Baseline Karnofsky Performance Scale (KPS)
Baseline Karnofsky Performance Scale (KPS)(Participants)Nivolumab + Standard Dose BevacizumabNivolumab + Low Dose BevacizumabTotal
70%111324
80%181735
90%151328
100%011
Unknown112
08

Study locations

2 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Dec 2020, 31 months.

Results were first posted in Jan 2025, 4 years after primary completion.

Of 197 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's 31 months is below that.

Counting every sponsor, half of 248 studies reached it within 55 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2018
First posted
Mar 2, 2018
StartActual
May 21, 2018
Primary completionActual
Dec 30, 2020
CompletionEst.
Jun 30, 2025
Results first posted
Jan 13, 2025
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03452579
Lead sponsor
David Peereboom
Responsible party
David Peereboom (Principal Investigator, Case Comprehensive Cancer Center) — Sponsor-investigator
First posted
Mar 2, 2018
Start date
May 21, 2018
Primary completion
Dec 30, 2020
Completion
Jun 30, 2025 (estimated)
Results posted
Jan 13, 2025
Last update
Feb 28, 2025

Study contacts

David Peereboom, MD
principal investigator · Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion